Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Lepu Biopharma Co. Ltd. Class H ( (HK:2157) ) has provided an update.
Lepu Biopharma Co., Ltd. reported that its 2025 annual general meeting was duly convened in Beijing and all resolutions were passed by shareholders through a poll. Items approved included the 2025 board, supervisory and financial reports, the 2026 financial budget, the 2025 profit distribution plan and the reappointment of Ernst & Young as auditor.
Shareholders also endorsed the appointment of a new supervisor, a change of the company’s registered address and amendments to the articles of association, alongside granting a general mandate to the board to issue additional shares. The broad support for these measures strengthens the company’s governance framework, provides flexibility for future capital raising and reflects continued shareholder confidence in its strategic direction.
More about Lepu Biopharma Co. Ltd. Class H
Lepu Biopharma Co., Ltd. is a pharmaceutical company based in the People’s Republic of China and listed in Hong Kong. The company focuses on biopharmaceutical research, development and commercialization, serving healthcare markets with innovative therapies and operating under PRC corporate and securities regulations.
Average Trading Volume: 12,745,844
Technical Sentiment Signal: Sell
Current Market Cap: HK$8.46B
See more insights into 2157 stock on TipRanks’ Stock Analysis page.